Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Socie...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilleece, Maria H., Shimoni, Avichai, Labopin, Myriam, Robinson, Stephen, Beelen, Dietrich, Socié, Gerard, Unal, Ali, Ganser, Arnold, Vitek, Antonin, Sengeloev, Henrik, Yakoub-Agha, Ibrahim, Tholouli, Eleni, Polge, Emmanuelle, Mohty, Mohamad, Nagler, Arnon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116335/
https://www.ncbi.nlm.nih.gov/pubmed/33980810
http://dx.doi.org/10.1038/s41408-021-00479-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116335/
https://www.ncbi.nlm.nih.gov/pubmed/33980810
http://dx.doi.org/10.1038/s41408-021-00479-3

Ejemplares similares